🇺🇸 FDA
Patent

US 8038997

Anti-marinobufagenin antibodies and methods for their use

granted A61KA61K2039/505A61P

Quick answer

US patent 8038997 (Anti-marinobufagenin antibodies and methods for their use) held by The United States of America as Represented by the Secretary of the Department of Health and Human Services expires Mon Oct 13 2031 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America as Represented by the Secretary of the Department of Health and Human Services
Grant date
Tue Oct 18 2011 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 13 2031 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
57
CPC classes
A61K, A61K2039/505, A61P, A61P9/00, A61P9/10